What is the dosing interval in hours for octreotide (Sandostatin) in a patient?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 24, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Octreotide Dosing Interval in Decompensated Cirrhotic Liver Disease (DCLD) for Hepatorenal Syndrome (HRS)

For variceal hemorrhage in cirrhosis, octreotide should be administered as a 50 mcg IV bolus followed by continuous IV infusion at 50 mcg/hour, which can be safely continued for 5 days or longer. 1

Dosing Regimen for Variceal Bleeding

The standard approach for octreotide in cirrhotic patients with variceal hemorrhage involves:

  • Initial bolus: 50 mcg IV 1
  • Continuous infusion: 50 mcg/hour IV 1
  • Duration: Can be used continuously for 5 days or even longer 1

This continuous infusion approach is preferred over intermittent dosing because octreotide and other somatostatin analogues are safe for extended continuous use, unlike vasopressin which can only be used for a maximum of 24 hours due to significant side effects 1.

Alternative Dosing for Other Indications

If octreotide is being used for other complications in DCLD patients (such as refractory diarrhea or other secretory conditions):

  • Subcutaneous dosing: 100-150 mcg three times daily (every 8 hours) 1
  • Dose escalation: Can be titrated up to 500 mcg three times daily subcutaneously 1
  • IV alternative: 25-50 mcg/hour by continuous infusion 1

Key Clinical Considerations

For variceal hemorrhage specifically, the continuous IV infusion is the evidence-based standard rather than intermittent dosing 1. The pharmacokinetics support this approach, as octreotide has a half-life of 1.7-1.9 hours with duration of action extending up to 12 hours depending on the clinical situation 2.

In patients with hepatic impairment (which applies to DCLD), octreotide elimination is prolonged with half-life increasing to 3.7 hours and total body clearance decreasing to 5.9 L/hr 2. However, this does not typically require dose adjustment for the standard continuous infusion protocol 1.

Common pitfall: Do not use intermittent bolus dosing every 8 hours for acute variceal bleeding—this is the regimen for carcinoid syndrome or secretory diarrhea, not for the hemodynamic control needed in variceal hemorrhage 1.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.